Thursday, February 29, 2024
HomeUS GovernmentVaxart gets BARDA funding for Phase 2 study of COVID-19 pill vaccine

Vaxart gets BARDA funding for Phase 2 study of COVID-19 pill vaccine

Vaxart (NASDAQ:VXRT) said it has been awarded funding by the US government for a large-scale Phase 2b study for its orally administered COVID-19 vaccine candidate.
The U.S. Biomedical Advanced Research and Development Authority, or BARDA, had awarded the company $9.27M for the clinical trial, which will be evaluating Vaxart’s oral pill vaccine against an approved mRNA vaccine. The study will be comprised of 10,000 participants.
Earlier this week, Vaxart disclosed that its president and CEO, Andrei Floriou, had resigned. Vaxart Chairman Michael Finney is serving as interim CEO until a successor is found.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments

Translate »
×